Hao Fu
Impact in
- Oncology top 5%
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
- Oncology 33
- Peptidase Inhibition and Analysis 10
- Cancer-related Molecular Pathways 9
- Co-authors
- Yaping Du (14 shared papers)Yong Jiang (7 shared papers)Zhong Zhu Liang (6 shared papers)Yourong Duan (16 shared papers)Haojun Chen (16 shared papers)Chuanrong Chen (9 shared papers)Chunlei Zhu (10 shared papers)Linqi Shi (8 shared papers)
- Journals
- BMC Cancer (4 papers)Advanced Science (4 papers)ACS Nano (4 papers)Biomaterials (4 papers)Clinical Cancer Research (3 papers)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Hao Fu
160 papers receiving 3.9k citations
Hao Fu's Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 774
- Biomaterials 400
- Cancer Research 380
- Biomedical Engineering 861
- Renewable Energy, Sustainability and the Environment 311
Countries citing papers authored by Hao Fu
This map shows the geographic impact of Hao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Fu more than expected).
Fields of papers citing papers by Hao Fu
This network shows the impact of papers produced by Hao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Fu. The network helps show where Hao Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Hao Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 167 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 213 | |
| 2 | 2023 | 158 | |
| 3 | 2020 | 144 | |
| 4 | Pt-Modified High Entropy Rare Earth Oxide for Efficient Hydrogen Evolution in pH-Universal Environments Hit paper breakdown → | 2024 | 135 |
| 5 | 2023 | 114 | |
| 6 | 2022 | 85 | |
| 7 | 2023 | 82 | |
| 8 | 2020 | 81 | |
| 9 | 2024 | 78 | |
| 10 | 2023 | 78 | |
| 11 | 2013 | 69 | |
| 12 | 2021 | 68 | |
| 13 | 2022 | 68 | |
| 14 | Superporous sponge prepared by secondary network compaction with enhanced permeability and mechanical properties for non-compressible hemostasis in pigs Hit paper breakdown → | 2024 | 63 |
| 15 | 2015 | 57 | |
| 16 | 2022 | 52 | |
| 17 | 2023 | 51 | |
| 18 | 2021 | 50 | |
| 19 | Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. | 1998 | 48 |
| 20 | 2020 | 48 |
About Hao Fu
Hao Fu is a scholar working on Oncology, Cancer Research, Biomedical Engineering, Endocrinology, Diabetes and Metabolism and Molecular Biology, having authored 167 papers that have together received 3.9k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (24 papers), Thyroid Cancer Diagnosis and Treatment (11 papers), Peptidase Inhibition and Analysis (10 papers), Radiopharmaceutical Chemistry and Applications (9 papers), Cancer-related Molecular Pathways (9 papers), Nanoparticle-Based Drug Delivery (8 papers), Advanced biosensing and bioanalysis techniques (7 papers) and Electrocatalysts for Energy Conversion (7 papers). The work is most often cited by research in Oncology (774 citations), Biomaterials (400 citations), Cancer Research (380 citations), Biomedical Engineering (861 citations) and Renewable Energy, Sustainability and the Environment (311 citations). Hao Fu has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Yaping Du, Yong Jiang, Zhong Zhu Liang, Yourong Duan, Haojun Chen, Chuanrong Chen, Chunlei Zhu, Linqi Shi, Minghui Xiao and Jianlin Shi. Their work appears in journals such as BMC Cancer, Advanced Science, ACS Nano, Biomaterials and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.